Treatment of ocular diseases with ophthalmic tapinarof compositions
AssigneeSol-Gel Technologies Ltd.
InventorsMoshe ARKIN, Marcel ZIGHELBOIM
Life of this patent
Estimating the term…
Loading patent…
AssigneeSol-Gel Technologies Ltd.
InventorsMoshe ARKIN, Marcel ZIGHELBOIM
Estimating the term…
The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), age-related macular degeneration, orbital myositis, and combinations thereof.
A topical ophthalmic composition for the treatment, prevention and/or amelioration of an ocular inflammatory disease or ocular degeneration disease, comprising from about 0.01% w/w to about 10.0% w/w tapinarof and a carrier suitable for topical ophthalmic administration.
Dependencies are inferred from the claim text.